Search the Newsreel

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares

CNL Price Today: Collective Mining Ltd Stock Price, Quote & Chart | MEXC

Colony Bankcorp (CBAN) outlines $19.75 cash or 0.94-share offer in FSRL merger

Gary Kelly Sells 15,007 Shares of Lincoln National (NYSE:LNC) Stock

Fuller & Thaler (NASDAQ: COLL) reports 5.03% beneficial stake in common stock

Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 5.03% in COLLEGIUM PHARMACEUTICAL, INC (COLL) common stock, totaling 1,632,780.71 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are held in accounts …

Fourthstone group discloses 0.79% Colony Bankcorp (CBAN) holding in passive stake

Fourthstone LLC and its related entities have disclosed a passive 0.79% stake in Colony Bankcorp (CBAN), holding 166,465 shares on behalf of advisory clients. This stake, acquired in the ordinary course of business, is explicitly stated not to be for the purpose of influencing …

Columbia Banking System, Inc. Declares Quarterly Dividend of $0.37 (NASDAQ:COLB)

CG Oncology (CGON) sees Foresite Capital report 4.9% beneficial stake via funds

Foresite Capital funds and James B. Tananbaum have reported beneficial ownership in CG Oncology (CGON) via a SCHEDULE 13G/A filing. While individual funds hold stakes under 5%, James B. Tananbaum, managing member of the involved Foresite Capital entities, is deemed to beneficially own 4,306,174 …

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss

Kura Oncology (KURA) investors report up to 9.7% beneficial ownership stakes

Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have reported significant beneficial ownership stakes in Kura Oncology, Inc. Montanova Capital and Aaron Cowen each own 9.7% of the common stock, while Averill Master Fund holds 8.8%. The reported shares are directly owned …

Citius Oncology's LYMPHIR has 44 ordering institutions, 383 July vials

Cardiff Oncology (CRDF) asks investors to double authorized common shares

Cardiff Oncology (CRDF) is seeking stockholder approval to significantly increase its authorized capital stock, specifically doubling its common stock from 150 million to 300 million shares. This move aims to provide the company with greater flexibility for future financings, strategic transactions, equity incentives, and …

TCG Crossover group (NASDAQ: ALXO) reports 4.2% ALX Oncology stake in 13G/A

TCG Crossover investment entities and Chen Yu have updated their reported ownership in ALX Oncology Holdings Inc. through an amended Schedule 13G filing. Chen Yu is deemed to beneficially own 4.2% of ALX Oncology's common stock, totaling 5,655,487 shares, through TCG Crossover Fund II, …

Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant

Pyxis Oncology's Interim CEO, Thomas Civik, has been granted a performance-based stock option for 250,956 shares, which vested on August 12, 2026. The option has an exercise price of $1.49 per share and an expiration date of February 3, 2036. This vesting occurred after …

Canada Pension Plan Investment Board (COLD) discloses 2.8% Americold stake in 13G/A

Canada Pension Plan Investment Board (CPP Investments) has filed an amended Schedule 13G/A, disclosing a 2.8% beneficial ownership stake in Americold Realty Trust, Inc. (COLD). This translates to 8,051,165 shares, over which CPP Investments holds sole voting and dispositive power. The filing indicates that …

Cullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & History

This article provides comprehensive information on Cullinan Therapeutics, Inc. (CGEM), including its current stock price, financial metrics, and a history of recent news and press releases. The company, a biopharmaceutical firm, focuses on developing cancer therapies and has announced several key clinical milestones and …

What's next for Coca-Cola after its Q2 earnings beat?

The Coca-Cola Company (KO [https://seekingalpha.com/symbol/KO]) reported robust second-quarter 2026 results [https://seekingalpha.com/news/4619526-coca-cola-projects-2026-comparable-eps-growth-of-9-percentminus-10-percent-with-organic] on July 29, 2026, delivering net revenues of $13.4 billion, up 7% year-over-year. The beverage giant's comparable earnings per share increased 11% to $0.97, handily beating analyst estimates alongside a solid 7% organic …

Coca-Cola (NYSE:KO) Draws Focus As Beverage Demand Stays Firm

Coca-Cola (NYSE:KO) is attracting renewed investor attention due to steady beverage demand and a market rotation towards defensive stocks. The company benefits from its strong global brand, diversified product portfolio beyond soda, and a softer dollar, which aids in converting overseas sales. Its consistent …

Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade

Kura Oncology (NASDAQ:KURA) saw its stock price rise 8% following an analyst upgrade from Wedbush, which increased its price target to $38 from $36 while maintaining an "outperform" rating. The company's Q2 results surpassed expectations with a narrower loss and higher revenue, driven by …

Meteora Capital (COLA) discloses 3.15% beneficial stake in Columbus Acquisition Corp

Meteora Capital, LLC and its managing member Vik Mittal have reported a beneficial ownership of 3.15% in Columbus Acquisition Corp/Cayman Islands Class A common stock, totaling 141,742 shares as of June 30, 2026. All shares held by Meteora Capital have shared voting and dispositive …

Columbia Bank continues Centennial State expansion with opening of Colorado Springs facility

Columbia Bank, headquartered in Tacoma, Wash., has expanded its presence in Colorado by opening its first commercial office and retail branch in Colorado Springs. This 5,500-square-foot facility, located in the downtown Trolley District, officially opened on July 15, 2026, and aims to serve businesses, …

Is Coca-Cola (KO) Quietly Redefining Its European Strategy Through Internal Leadership Moves?

A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40

This article provides a quick overview of analyst ratings for Kura Oncology (KURA.US), noting a forecast price range of $23 to $40. It indicates that the company is currently receiving a 'Buy' rating from analysts, reflecting positive sentiment. The information is presented as a …

JPMorgan Chase & Co. Has Lowered Expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price

India Glycols Q1FY27 consolidated profit up 32% to ₹96.8 crore

Crédit Agricole S.A.: Objectif de Cours et Consensus des Analystes | ACA | FR0000045072

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9,353,553 shares of Citius Oncology, Inc. common stock, which represents a 9.99% stake in the company. They hold shared voting and dispositive power over these shares, which are directly held by Armistice …

Kura Oncology FY2029 EPS Cut by Brookline Capital Markets

Columbia Banking System declares $0.37 quarterly dividend

Columbia Banking System, Inc. (NASDAQ:COLB) has announced that its Board of Directors approved a quarterly cash dividend of $0.37 per common share. This dividend is scheduled to be paid on September 14, 2026, to shareholders of record as of August 28, 2026. The company …

Zacks Research Has Optimistic Outlook of LECO Q3 Earnings

CG Oncology (CGON): RTW Investments takes 9.7% position, holding 8.5M shares

RTW Investments, LP and Roderick Wong, M.D. have reported a 9.7% beneficial ownership in CG Oncology, Inc. (CGON), totaling 8,514,590 common shares. These shares are held by RTW-managed funds, with RTW Investments and Dr. Wong sharing voting and dispositive power. The ownership percentage is …

Nicolet Bankshares Inc. (NYSE:NIC) Receives Average Rating of "Moderate Buy" from Analysts

Nicolet Bankshares Inc. (NYSE:NIC) has received an average rating of "Moderate Buy" from analysts, with a consensus 12-month price target of $183.00. The company recently reported strong quarterly earnings of $2.99 per share and revenue of $177.75 million, both exceeding analyst expectations. Despite positive …

Collective Mining Ltd CNL Earnings Miss Estimates by 72.2%

COLLEGIUM PHARMACEUTICAL INC : NEEDHAM CUTS TARGET PRICE TO $46 FROM $56

Needham has revised its target price for Collegium Pharmaceutical Inc (NASDAQ: COLL) downwards from $56 to $46. This article, published on August 7th, highlights the analyst's updated outlook on the pharmaceutical company.

Sudarshan Colorants India Share Price Target 2027 to 2030: Analyst

Jiangsu Innovative Ecological New Materials Sets Board Meeting on Interim Results and Dividend